SubHero Banner

Carvykti® (ciltacabtagene autoleucel) – Expanded indication

April 5, 2024 - Johnson & Johnson announced the FDA approval of Carvykti (ciltacabtagene autoleucel), for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.

Download PDF